Female Autoimmune Disorders with Infertility: A Narrative Review | ||
| Al- Anbar Medical Journal | ||
| Article 2, Volume 19, Issue 1, June 2023, Pages 3-9 PDF (968.51 K) | ||
| Document Type: Review articles | ||
| DOI: 10.33091/amj.2023.138475.1022 | ||
| Authors | ||
| Muhjah Falah Hassan* 1; Ali M. Kadim Al-Tuma2 | ||
| 1Department of anatomy,college of medicine,karbala university | ||
| 2department of internal medicine/college of medicine/karbala university | ||
| Abstract | ||
| Autoimmunity is a condition in which the immune system cannot recognize the self from non-self-antigens. Autoimmunity is relatively more common in females than males. The process of embryo implantation is considered the most significant restricting factor in female reproduction. The immunological system of the females may affect the success or failure of pregnancy by its effect on extremely important steps from ovulation to implantation processes, thus ensuring the importance of autoimmunity for women in sub-fertility. The association between autoimmunity and female reproduction receives increased attention nowadays. A successful conception is a result of multiple complex interactions between the developed embryo and the receptive uterus and is usually under immune-hormonal control. In certain circumstances, the female ovary can be a target of an autoimmune attack, like some organ‐specific or systemic autoimmune disorders subsequently resulting in clinically significant ovarian dysfunction, implantation failure, and sub-fertility. Consequently, the effect of a specific auto-antibody on the etiology of infertility remains unknown. This review focused on auto-antibodies that may affect female fertility. | ||
| Keywords | ||
| Autoimmunity; Sub-fertility; Auto-antibodies; Pregnancy; Implantation Failure | ||
| References | ||
|
[1] E. C. W. Group, “Physiopathological determinants of human infertility,” Hum. Reprod. Update, vol. 8, no. 5, pp. 435–447, 2002. [2] S. Medenica et al., “The role of cell and gene therapies in the treatment of infertility in patients with thyroid autoimmunity,” Int. J. Endocrinol., vol. 2022, 2022. [3] M. Pujalte et al., “A ZP1 gene mutation in a patient with empty follicle syndrome: A case report and literature review,” Eur. J. Obstet. Gynecol. Reprod. Biol., vol. 280, pp. 193–197, 2023. [4] O. Parolini et al., “Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells,” Stem Cells, vol. 26, no. 2, pp. 300–311, 2008. [5] Y. Li, L. Zhang, P. Yu, X. Cai, N. Li, and B. Ma, “The efficacy of sequential day 3 embryo and blastocyst transfer in patients with repeated implantation failure,” Eur. J. Obstet. Gynecol. Reprod. Biol., 2023. [6] K. Vinketova, M. Mourdjeva, and T. Oreshkova, “Human decidual stromal cells as a component of the implantation niche and a modulator of maternal immunity,” J. Pregnancy, vol. 2016, 2016. [7] M. Tavares Pereira et al., “Utero-placental expression and functional implications of HSD11B1 and HSD11B2 in canine pregnancy,” Biol. Reprod., p. ioac214, 2023. [8] X. Meng, L. Peng, X. Wei, and S. Li, “FOXO3 is a potential biomarker and therapeutic target for premature ovarian insufficiency,” Mol. Med. Rep., vol. 27, no. 2, pp. 1–8, 2023. [9] V. V Chopyak, H. Koval, A. Havrylyuk, K. Lishchuk-Yakymovych, H. Potomkina, and M. K. Kurpisz, “Immunopathogenesis of endometriosis–a novel look at an old problem,” Cent. Eur. J. Immunol., vol. 47, no. 1, 2022. [10] C. Ticconi et al., “Antinuclear antibodies positivity in women in reproductive age: from infertility to adverse obstetrical outcomes–A meta-analysis,” J. Reprod. Immunol., p. 103794, 2023. [11] E. C. Vogt et al., “Premature menopause and autoimmune primary ovarian insufficiency in two international multi-center cohorts,” Endocr. Connect., vol. 11, no. 5, 2022. [12] A. Hasegawa, “Infertility and Anti-ZP Antibody (AZPA),” in Gamete Immunology, Springer, 2022, pp. 261–266. [13] Z. Su, W. Su, C. Li, P. Ding, and Y. Wang, “Identification and immune features of cuproptosis-related molecular clusters in polycystic ovary syndrome,” Sci. Rep., vol. 13, no. 1, p. 980, 2023. [14] S. Toor, J. E. Yardley, and Z. Momeni, “Type 1 Diabetes and the Menstrual Cycle: Where/How Does Exercise Fit in?,” Int. J. Environ. Res. Public Health, vol. 20, no. 4, p. 2772, 2023. [15] A. Adone and D. G. Fulmali, “Polycystic Ovarian Syndrome in Adolescents,” Cureus J. Med. Sci., vol. 15, no. 1, 2023. [16] Z. Shojaei, R. Jafarpour, S. Mehdizadeh, H. Bayatipoor, S. Pashangzadeh, and M. Motallebnezhad, “Functional prominence of natural killer cells and natural killer T cells in pregnancy and infertility: A comprehensive review and update,” Pathol. Pract., p. 154062, 2022. [17] B. F. Barrier, “Immunology of endometriosis,” Clin. Obstet. Gynecol., vol. 53, no. 2, pp. 397–402, 2010. [18] Y. Zhong, X. Zhou, C. Hou, and W. Li, “Effect of Danefukang on symptoms and biomarkers in women with endometriosis,” Taiwan. J. Obstet. Gynecol., vol. 58, no. 2, pp. 218–222, 2019. [19] S. Vassiliadis, K. Relakis, A. Papageorgiou, and I. Athanassakis, “Endometriosis and infertility: a multi-cytokine imbalance versus ovulation, fertilization and early embryo development,” Clin. Dev. Immunol., vol. 12, no. 2, pp. 125–129, 2005. [20] A. Sarapik, K. Haller‐Kikkatalo, M. Utt, K. Teesalu, A. Salumets, and R. Uibo, “Serum anti‐endometrial antibodies in infertile women–potential risk factor for implantation failure,” Am. J. Reprod. Immunol., vol. 63, no. 5, pp. 349–357, 2010. [21] H. Greenbaum, D. H. Decter, and V. H. Eisenberg, “Endometriosis and autoimmunity: Can autoantibodies be used as a non-invasive early diagnostic tool?,” Autoimmun. Rev., vol. 20, no. 5, p. 102795, 2021. [22] S. Zhang et al., “Repeated controlled ovarian stimulation-induced ovarian and uterine damage in mice through the PI3K/AKT signaling pathway,” Hum. Cell, vol. 36, no. 1, pp. 234–243, 2023. [23] J. Khizroeva et al., “Infertility in women with systemic autoimmune diseases,” Best Pract. Res. Clin. Endocrinol. Metab., vol. 33, no. 6, p. 101369, 2019. [24] E. S. Pires, “Multiplicity of molecular and cellular targets in human ovarian autoimmunity: an update,” J. Assist. Reprod. Genet., vol. 27, pp. 519–524, 2010. [25] S. Boussaid et al., “The effects of autoimmune rheumatic-related diseases on male reproductive health: A systematic review,” J. Reprod. Immunol., vol. 150, p. 103472, 2022. [26] L. Putowski, D. Darmochwal-Kolarz, J. Rolinski, J. Oleszczuk, and J. Jakowicki, “The immunological profile of infertile women after repeated IVF failure (preliminary study),” Eur. J. Obstet. Gynecol. Reprod. Biol., vol. 112, no. 2, pp. 192–196, 2004. [27] R. Yanagimachi, “Mysteries and unsolved problems of mammalian fertilization and related topics,” Biol. Reprod., vol. 106, no. 4, pp. 644–675, 2022. [28] W. Zhang and F. Wu, “Effects of adverse fertility-related factors on mitochondrial DNA in the oocyte: a comprehensive review,” Reprod. Biol. Endocrinol., vol. 21, no. 1, pp. 1–12, 2023. [29] F. Rafael et al., “The combined effect of BMI and age on ART outcomes,” Hum. Reprod., p. dead042, 2023. [30] N. Nitsche and S. R. Hayford, “Preferences, partners, and parenthood: Linking early fertility desires, marriage timing, and achieved fertility,” Demography, vol. 57, no. 6, pp. 1975–2001, 2020. [31] C. Mendoza-Pinto, M. García-Carrasco, and R. Cervera, “Microorganisms in the Pathogenesis and Management of Anti-phospholipid Syndrome (Hughes Syndrome),” in Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases: Volume II: Kidney, Central Nervous System, Eye, Blood, Blood Vessels & Bowel, Springer, 2023, pp. 341–357. [32] D. J. Arachchillage and C. Pericleous, “Evolution of antiphospholipid syndrome,” in Seminars in Thrombosis and Hemostasis, 2023. [33] R. Sauer, R. Roussev, R. S. Jeyendran, and C. B. Coulam, “Prevalence of antiphospholipid antibodies among women experiencing unexplained infertility and recurrent implantation failure,” Fertil. Steril., vol. 93, no. 7, pp. 2441–2443, 2010. [34] G. Petrovic, S. Pasic, and I. Soldatovic, “Association of Antiphospholipid Antibodies with Clinical Manifestations in Children with Systemic Lupus Erythematosus,” J. Clin. Med., vol. 12, no. 4, p. 1424, 2023. [35] J. Carré, G. Jourdi, N. Gendron, D. Helley, P. Gaussem, and L. Darnige, “Recent advances in anticoagulant treatment of immune thrombosis: A focus on direct oral anticoagulants in heparin-induced thrombocytopenia and anti-phospholipid syndrome,” Int. J. Mol. Sci., vol. 23, no. 1, p. 93, 2022. [36] Y. Shi et al., “Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications,” Rheumatology, vol. 62, no. 1, pp. 256–263, 2023. [37] N. J. Sebire, H. Fox, M. Backos, R. Rai, C. Paterson, and L. Regan, “Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure,” Hum. Reprod., vol. 17, no. 4, pp. 1067–1071, 2002. [38] G. Girardi, D. Yarilin, J. M. Thurman, V. M. Holers, and J. E. Salmon, “Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction,” J. Exp. Med., vol. 203, no. 9, pp. 2165–2175, 2006. [39] P. L. Meroni, M. O. Borghi, C. Grossi, C. B. Chighizola, P. Durigutto, and F. Tedesco, “Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?,” Nat. Rev. Rheumatol., vol. 14, no. 7, pp. 433–440, 2018. [40] R. Mazzilli et al., “The role of thyroid function in female and male infertility: A narrative review,” J. Endocrinol. Invest., vol. 46, no. 1, pp. 15–26, 2023. [41] M. Abalovich et al., “Subclinical hypothyroidism and thyroid autoimmunity in women with infertility,” Gynecol. Endocrinol., vol. 23, no. 5, pp. 279–283, 2007. [42] E. Gotoh, “Chemical-Induced Premature Chromosome Condensation Protocol,” in Chromosome Analysis: Methods and Protocols, Springer, 2022, pp. 41–51. [43] S. Chen et al., “Antinuclear antibodies positivity is a risk factor of recurrent pregnancy loss: a meta-analysis,” in Seminars in Arthritis and Rheumatism, 2020, vol. 50, no. 4, pp. 534–543. [44] N. Freitag et al., “Are uterine natural killer and plasma cells in infertility patients associated with endometriosis, repeated implantation failure, or recurrent pregnancy loss?,” Arch. Gynecol. Obstet., vol. 302, pp. 1487–1494, 2020. [45] S. Giulini et al., “Chronic endometritis in recurrent implantation failure: Use of prednisone and IVF outcome,” J. Reprod. Immunol., vol. 153, p. 103673, 2022. [46] E. S. Pires, F. R. Parikh, P. V Mande, S. A. Uttamchandani, S. Savkar, and V. V Khole, “Can anti-ovarian antibody testing be useful in an IVF-ET clinic?,” J. Assist. Reprod. Genet., vol. 28, pp. 55–64, 2011. [47] H. Shibahara, “Causes of Immune Infertility in Women with Anti-sperm Antibody (ASA),” in Gamete Immunology, Springer, 2022, pp. 35–53. [48] J. Smitz, C. Wolfenson, S. Chappel, and J. Ruman, “Follicle-stimulating hormone: a review of form and function in the treatment of infertility,” Reprod. Sci., vol. 23, pp. 706–716, 2016. [49] V. AS et al., "Role of anti-sperm antibodies in infertility, pregnancy, and potential for contraceptive and antifertility vaccine designs: Research progress and pioneering vision,” Vaccines, vol. 7, no. 3, p. 116, 2019. [50] K. Haller et al., “Putative predictors of antibodies against follicle‐stimulating hormone in female infertility: a study based on in vitro fertilization patients,” Am. J. Reprod. Immunol., vol. 57, no. 3, pp. 193–200, 2007. [51] K. Haller, C. Mathieu, K. Rull, K. Matt, M. C. Béné, and R. Uibo, “IgG, IgA and IgM antibodies against FSH: serological markers of pathogenic autoimmunity or of normal immunoregulation?,” Am. J. Reprod. Immunol., vol. 54, no. 5, pp. 262–269, 2005. [52] L. Shen et al., “The function and mechanism of action of uterine microecology in pregnancy immunity and its complications,” Front. Cell. Infect. Microbiol., vol. 12, p. 1833, 2023. [53] Y. S. Lim and H. Shin, “CD8 tissue resident memory T cells bridge the gap between humoral and cell-mediated immunity,” Mucosal Immunol., 2023. [54] M. KAMADA et al., “Etiological implication of autoantibodies to zona pellucida in human female infertility,” Am. J. Reprod. Immunol., vol. 28, no. 2, pp. 104–109, 1992. [55] Y. Fang, R. Wu, J. M. Lee, L. H. M. Chan, and K. Y. J. Chan, “Microfluidic in-vitro fertilization technologies: Transforming the future of human reproduction,” TrAC Trends Anal. Chem., p. 116959, 2023. [56] J. Tang, M. Tan, S. Liao, M. Pang, and J. Li, “Recent progress in the biology and physiology of BMP-8a,” Connect. Tissue Res., pp. 1–10, 2023. [57] M. A. Christou, A. Kalpatsanidis, and E. M. Kolibianakis, “Diabetes Mellitus and Infertility,” in Comprehensive Clinical Approach to Diabetes During Pregnancy, Springer, 2022, pp. 377–393. [58] T. Nishimoto, T. Mori, I. Yamada, and T. Nishimura, “Autoantibodies to zona pellucida in infertile and aged women,” Fertil. Steril., vol. 34, no. 6, pp. 552–556, 1980. [59] H. J. A. Carp, C. Selmi, and Y. Shoenfeld, “The autoimmune bases of infertility and pregnancy loss,” J. Autoimmun., vol. 38, no. 2–3, pp. J266–J274, 2012. [60] A. M. Seid and D. A. Terefe, “Non-surgical castration methods to control stray dog population, a review,” Online J. Anim. Feed Res, vol. 9, no. 6, pp. 233–240, 2019. [61] S. Takamizawa, H. Shibahara, T. Shibayama, and M. Suzuki, “Detection of antizona pellucida antibodies in the sera from premature ovarian failure patients by a highly specific test,” Fertil. Steril., vol. 88, no. 4, pp. 925–932, 2007. [62] B. S. Dunbar et al., “The mammalian zona pellucida: its biochemistry, immunochemistry, molecular biology, and developmental expression,” Reprod. Fertil. Dev., vol. 6, no. 3, pp. 331–347, 1994. [63] J. Dietl, J. Freye, and L. Mettler, “Fertility inhibition using low‐dose immunization with porcine zonae pellucidae,” Am. J. Reprod. Immunol., vol. 2, no. 3, pp. 153–156, 1982. [64] C. Cariño et al., “Localization of species conserved zona pellucida antigens in mammalian ovaries,” Reprod. Biomed. Online, vol. 4, no. 2, pp. 116–126, 2002. [65] G. Calongos, A. Hasegawa, S. Komori, and K. Koyama, “Harmful effects of anti-zona pellucida antibodies in folliculogenesis, oogenesis, and fertilization,” J. Reprod. Immunol., vol. 79, no. 2, pp. 148–155, 2009. [66] Y. Y. Cai et al., “Serum and follicular fluid thyroid hormone levels and assisted reproductive technology outcomes,” Reprod. Biol. Endocrinol., vol. 17, pp. 1–8, 2019. [67] K. Kaur and V. Prabha, “Immunocontraceptives: new approaches to fertility control,” Biomed Res. Int., vol. 2014, 2014.
| ||
|
Statistics Article View: 411 PDF Download: 511 |
||